FDA in Fact-Finding Mode on CBD

June 20, 2019 | Eric D. Fader | Cannabis | FDA | Legislation and Public Policy | Pharmaceuticals

The U.S. Food and Drug Administration (FDA) released a Consumer Update regarding cannabidiol (CBD) on June 14. Observing that CBD “seems to be available almost everywhere,” the FDA noted that the science, safety, and quality of CBD-containing products are unproven and said that it is working to learn more about the safety of CBD.

Unapproved drugs containing CBD have not been subject to FDA’s normal drug approval process. Nonetheless, some companies have claimed that their CBD products can prevent, treat or cure cancer, Alzheimer’s disease, psychiatric disorders, diabetes, or other conditions. The FDA also pointed out that it is illegal to market CBD as a dietary supplement.

In addition to seeking more “high quality, scientific information about the safety and potential uses of CBD,” the FDA is evaluating whether its regulations that apply to CBD products need to be updated.

Share this article:
show more

Get legal updates and news delivered to your inbox